Skip to main content
OpenTrials
Completed

NCT Number: NCT02186756

A Randomized Controlled Trial to Evaluate the Effectiveness of Electromyography (EMG)-Biofeedback in Patients With Fibromyalgia

The purpose of this study is to determine whether EMG-Biofeedback is effective in the treatment of Fibromyalgia.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

About this study

The objective of this randomized controlled trial is to evaluate the effectiveness of EMG-biofeedback in patients with Fibromyalgia. The assessors are blinded to the group assignment. There are three time points of assessment: before intervention, at the end of treatment (T1) and 3-months follow-up (T2). Patients are recruited from the waiting list of the Fibromyalgia day hospital program at the University Hospital Munich fulfilling the inclusion criteria. The intervention group is treated with 14 sessions of EMG-biofeedback during eight weeks in addition to usual care. The control group receives usual care only. The main specific aim is to assess the change in fibromyalgia specific health status.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • fibromyalgia according to the American Congress of Rheumatology (ACR)-criteria and the criteria.
  • female gender
  • age between 18 and 65
  • cognitive ability and sufficient German language skills to fill in health status questionnaires
  • signed informed consent

Exclusion criteria

  • major medical disorders, i.e. cancer, chronic heart failure New York Heart Association (NYHA) IV or asthma requiring cortisone medication
  • suffering from psychosis or major affective disorders
  • substance abuse
  • co-medication with opiates or benzodiazepine
  • transmeridian flight in the last weeks
  • shift-work
  • gravity

Treatment and study plan

EMG-Biofeedback and Usual care

Other

Please refer to arm description

Other names: Schuhfried Biofeedback apparatus

Primary outcomes

  1. Fibromyalgia Impact Questionnaire (FIQ)

    Time frame: Change from baseline to 3 months

    The primary outcome measure was the Fibromyalgia Impact Questionnaire (FIQ). The FIQ is a disease specific multidimensional self-administered instrument that covers the dimensions physical functioning (11 items), well-being (1 item), work situation (2 items), pain (1 item), fatigue /sleep (2 items), stiffness (2 items) and psychological symptoms (2 items). Scoring ranges from 0 to 80 with the latter number being the worst case. The FIQ Total Score gives a summary of patients' impairment and is recommended as a highly sensitive measure of change in Fibromyalgia treatment programs and clinical studies. In this study the validated German version was used.

Secondary outcomes

  1. Fibromyalgia Impact Questionnaire (FIQ)

    Time frame: Change from baseline to End of Treatment (8 weeks after baseline)

  2. Short-Form 36 (SF-36)

    Time frame: Change from baseline to End of treatment (8 weeks after baseline)

    The SF-36 is a widely used measure of health-related quality of life with 36 items. It yields an eight-scale profile of scores which are Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health.

  3. Short-Form 36 (SF-36)

    Time frame: Change from baseline to 3 months

  4. self-rated Patients' Global Clinical Impression of Change Score

    Time frame: End of Treatment (8 weeks after baseline)

    Change of health was directly measured by the self-rated Patients' Global Clinical Impression of Change Score, which is a validated measure of overall change compared with study onset, including six possible scores from "very much worse" (score 1) to "very much better" (score 6).

  5. self-rated Patients' Global Clinical Impression of Change Score

    Time frame: 3 months

  6. Beck Depression Inventory (BDI)

    Time frame: Change from baseline to End of treatment (8 weeks after baseline)

    This questionnaire was developed and validated for patients with depression and has been applied in clinical trials of patients with Fibromyalgia as well. It contains 21 items that assess the cognitive, affective and neurovegetative factors associated with depression.

  7. Beck Depression Inventory (BDI)

    Time frame: Change from baseline to 3 months

  8. Symptom Checklist 90 Revised (SCL-90-R)

    Time frame: Change from baseline to 3 Months

    the Symptom Checklist 90 Revised (SCL-90-R) was used for measuring psychological distress. It generates 9 specific scales, one additional unspecific scale and three general scores. The 9 dimensions of the scale are as follows: SCL 1 = somatization; SCL 2 = obsessive-compulsive symptoms; SCL 3 = interpersonal sensitivity; SCL 4 = depression; SCL 5 = anxiety; SCL 6 = hostility; SCL 7 = phobic anxiety; SCL 8 = paranoid ideation; SCL 9 = psychoticism. The Global Severity Index serves as a measure of psychological distress.

  9. Tender Point Score

    Time frame: Change from baseline to End of treatment (8 weeks after baseline)

    It consists of a body diagram, where patients can rate the pain intensity at 24 locations of the front and the back side of the body. It allows calculating a total score for the whole body, as well as specific local scores.

  10. Tender Point Score

    Time frame: Change from baseline to 3 months

  11. Tender Point Count

    Time frame: Change from baseline to End of treatment (8 weeks after baseline)

    According to the Tender point manual the examiner applied discrete pressure of 4 kg/cm² to each of the 18 Fibromyalgia typical Tender Points. When the patients expressed pain, the tender point was considered positive.

  12. Pressure Pain Threshold

    Time frame: Change from baseline to End of Treatment (8 weeks after baseline)

    For measuring the Pressure Pain Threshold, the assessor first searched for an induration with pressure pain in the trapezius muscle pars descendens on each side of the muscle. The palpated part of the muscle was always located above or on a line between the acromioclavicular joint and the spinous process of vertebrae C 7. These two structures also served as coordinates to write down the exact place of the palpated taut band. Second, using a Fischer dolorimeter with a stamp of 1 cm², the examiner applied vertical pressure to the selected point and successively augmented the pressure until the patient signalled pain. In this way, the pressure pain threshold was measured in kg/cm².

Sponsors and collaborators

Lead sponsor

Ludwig-Maximilians - University of Munich

Other

Registry information

Official study title

Biofeedback in Patients With Fibromyalgia - a Randomized Controlled Trial

Important dates

Study start
2005
Primary completion
2006
Study completion
2006
First posted
Jul 10, 2014
Registry last updated
Jul 10, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.